2013
DOI: 10.1161/strokeaha.112.670976
|View full text |Cite
|
Sign up to set email alerts
|

Brain and Circulating Levels of Aβ1–40 Differentially Contribute to Vasomotor Dysfunction in the Mouse Brain

Abstract: Background and Purpose Amyloid-β (Aβ), a peptide that accumulates in the brain and circulates in the blood of patients with Alzheimer’s disease (AD), alters the regulation of cerebral blood flow (CBF) and may contribute to the brain dysfunction underlying the dementia. However, the contributions of brain and circulating Aβ1–40 to the vascular dysfunction have not been elucidated. Methods we used transgenic mice overexpressing mutated forms of the amyloid precursor protein in which Aβ1–40 is elevated in blood… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

5
48
0

Year Published

2013
2013
2024
2024

Publication Types

Select...
9

Relationship

2
7

Authors

Journals

citations
Cited by 47 publications
(53 citation statements)
references
References 42 publications
(72 reference statements)
5
48
0
Order By: Relevance
“…The precise mechanisms underlying these associations remain unclear but amyloid production and accumulation are likely to be responsible for synaptic and neuronal degeneration and gray matter atrophy (Hardy and Selkoe, 2002). Animal studies have shown plasma Ab to be negatively correlated with density of neurons accumulating Ab deposits (Roy et al, 2014) and that elevations in both brain and circulating Ab levels can induce cerebrovascular dysfunction, with distinct and additive effects (Park et al, 2013). Cerebrovascular damage (e.g., brain hypoperfusion, hypoxia) may lead to neurodegenerative changes, or accumulation and reduced clearance of Ab from the brain, further amplifying neuronal injury and neurodegeneration (Bell et al, 2010;Deane et al, 2004).…”
Section: Discussionmentioning
confidence: 99%
“…The precise mechanisms underlying these associations remain unclear but amyloid production and accumulation are likely to be responsible for synaptic and neuronal degeneration and gray matter atrophy (Hardy and Selkoe, 2002). Animal studies have shown plasma Ab to be negatively correlated with density of neurons accumulating Ab deposits (Roy et al, 2014) and that elevations in both brain and circulating Ab levels can induce cerebrovascular dysfunction, with distinct and additive effects (Park et al, 2013). Cerebrovascular damage (e.g., brain hypoperfusion, hypoxia) may lead to neurodegenerative changes, or accumulation and reduced clearance of Ab from the brain, further amplifying neuronal injury and neurodegeneration (Bell et al, 2010;Deane et al, 2004).…”
Section: Discussionmentioning
confidence: 99%
“…Experiments were performed in Tg-SwDI male mice at 3, 18, and 24 months on a C57BL/6 background. 11,14 Age-matched C57BL/6 male mice were used as wild-type (WT) controls.…”
Section: Methodsmentioning
confidence: 99%
“…Thus, the increase in cerebral blood flow (CBF) evoked by neural activity (functional hyperemia), a key mechanism that matches the metabolic needs of active neurons with the delivery of energy substrates via blood flow, and the ability of brain endothelial cells to control CBF are markedly impaired. 14 However, because previous studies were conducted in 3-month-old Tg-SwDI mice before amyloid deposition, the relationships linking vascular dysfunction, amyloid accumulation, and vascular damage have not been established. Furthermore, the mechanisms of the cerebrovascular dysfunction in Tg-SwDI mice remain to be defined.…”
mentioning
confidence: 99%
“…27 These observations are consistent with findings published in other longitudinal studies, suggesting that plasma levels of Ab peptides increase in the preclinical phase of AD, successively declining with the progression of clinical dementia, reflecting the deposition of Ab peptides in the brain. [28][29][30][31][32][33] No substantial differences concerning clinical phenotype and course were evidenced comparing heterozygous and homozygous patients (table e-2). In these affected persons, homozygosity for the APP A713T mutation does not aggravate the clinical picture of the disease, which is in line with the classic definition of dominance.…”
mentioning
confidence: 92%